The Pharma Data
APRIL 22, 2023
Results at Day 28 showed that people with cancer treated with Veklury had a significantly lower risk for mortality compared to people with cancer that were not treated with Veklury (HR:0.67, 95% CI:0.59-0.75; This finding was seen across all VOC at Day 28: pre-Delta, 25% (HR:0.75, 95% CI:0.61-0.92; 0.75; p<0.0001).
The Pharma Data
NOVEMBER 17, 2021
Food and Drug Administration (FDA) includes clinical data from the Phase2/3 EPIC-HR ( Evaluation of Protease Inhibition for COVID-19 in High- Threat Cases) interim analysis. PF-07321332 inhibits viral replication at a stage known as proteolysis, which occurs before viral RNA replication. This submission to theU.S. FDA in October 2021.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 19, 2021
.” PF-07321332 is designed to block the exertion of the SARS-CoV-2-3CL protease, an enzyme that the coronavirus needs to replicate, at a stage known as proteolysis-which occurs before viral RNA replication.
The Pharma Data
SEPTEMBER 6, 2021
Over 70% of breast cancer cases are hormone receptor (HR)-positive, and there is a need for more effective and tolerable treatments, since up to 30% of patients develop resistance to standard of care treatments and in the adjuvant setting half of patients stop treatment due to the toll of side effects. Lung Cancer Highlights. Real world data.
The Pharma Data
NOVEMBER 24, 2020
0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 Oxlumo works by degrading HAO1 messenger RNA and reducing the synthesis of GO, which inhibits hepatic production of oxalate – the toxic metabolite responsible for the clinical manifestations of PH1. Visit OXLUMO.com for more information, including full Prescribing Information.
Pfizer
AUGUST 15, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. No dosage adjustment is needed in patients with mild renal impairment.
The Pharma Data
JUNE 7, 2023
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA® (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA Moderna, Inc.
Expert insights. Personalized for you.
40 
Let's personalize your content